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Introduction {#sec1}
============

Growth is a key cellular process orchestrated by intrinsic and extrinsic factors that engage signaling pathways and transcriptional programs for the upregulation of macromolecular synthesis and for increases in both cell size and mass ([@bib63]). During nervous system development, cell growth is subject to spatial and temporal constraints because neurons grow in a highly polarized and localized fashion. An example of how spatially segregated neuronal growth can be organized is exemplified during axon morphogenesis. At that time, growth is manifested as axon elongation and axon branching, both of which are developmentally and operationally separated ([@bib28], [@bib34]) but, nevertheless, are expected to be coordinated with an overall neuronal growth capacity.

An established growth-promoting signaling pathway in neurons is controlled by the phosphoinositide 3-kinases (PI3Ks) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN). PI3K synthesizes the generation of phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P~3~) at the plasma membrane, whereas PTEN hydrolyzes PI(3,4,5)P~3~ at the D3 position of the inositol ring, thereby directly antagonizing PI3K and downstream AKT/GSK3/mTORC1 growth-associated signaling pathways ([@bib33]). PI3K activity is indispensable for controlling multiple growth processes, and inactivating *PTEN* mutations are associated with sporadic cancers; overgrowth syndromes, such as PTEN hamartoma tumor syndrome; and autism spectrum disorders ([@bib24], [@bib32]).

Precise spatiotemporal regulation of PI3K/PTEN-generated PI(3,4,5)P~3~ is essential for the proper reorganization of the plasma membrane actin cytoskeleton to support cell morphology and migration in different cell types ([@bib20], [@bib26], [@bib37]). In neurons, in particular, localized production of PI(3,4,5)P~3~ is associated with hallmarks of neuronal morphology such as induction and elongation of neurites, dendritic spine morphogenesis and function, and axon branch morphogenesis ([@bib18], [@bib22], [@bib31], [@bib41], [@bib49]). In axons, localized production of PI(3,4,5)P~3~ supports the initiation of F-actin patches, which give rise to filopodia protrusions along the axon shaft ([@bib18], [@bib29], [@bib54]). These filopodial protrusions are considered precursors for axon branches, which mature by subsequent invasion and stabilization of microtubules and ultimately form the basis of neuronal connectivity in the adult brain ([@bib28]).

Although generation of PI(3,4,5)P~3~ during axon growth and branching has been well documented ([@bib28], [@bib29]), the mechanisms involving PTEN regulation deserve further attention, given that they can either expand or blunt the signaling output of the PI3K pathway by altering PI(3,4,5)P~3~ plasma membrane concentration and localization ([@bib31]). This is particularly relevant because PTEN is highly abundant in neurons and extremely efficient in confining and limiting PI3K-dependent growth in the axon, especially during early development when axons elongate to reach their targets ([@bib8], [@bib10], [@bib15], [@bib68]). How neurons overcome that growth barrier to allow collateral branching is not fully understood.

Here, we identify and characterize a PTEN membrane protein association, which controls PTEN activity. The protein complex incorporates plasticity-related gene 2 (PRG2), a transmembrane protein belonging to the family of lipid phosphate phosphatase-related (also known as LPPR) proteins. Our data indicate that PRG2 associates with PTEN and organizes PI(3,4,5)P~3~-mediated cellular responses in neurons during axon filopodia initiation and branch formation.

Results {#sec2}
=======

PTEN Interacts with the Neuronal Membrane Protein PRG2 {#sec2.1}
------------------------------------------------------

We set out to identify proteins involved in regulating the sub-cellular localization and/or function of PTEN in neurons using mass spectrometry ([@bib59]). Among the protein interactions, we identified PRG2 as a PTEN binding partner. We first confirmed the PRG2-PTEN association by performing endogenous co-immunoprecipitation in embryonic day 18 (E18) rat brain lysates as well as in days *in vitro* (DIV) 9 cortical neuron cultures ([Figure 1](#fig1){ref-type="fig"}A). PRG2 (or LPPR3) is a member of the LPPR protein family whose members show high homology with bioactive lipid-inactivating phosphatases but lack catalytic activity ([@bib39], [@bib51], [@bib55]). PRG2 is closely related to its better functionally characterized homolog PRG1 ([@bib4], [@bib35], [@bib56]); both proteins share the common domain structure with six transmembrane regions forming an extracellular oriented pseudo-LPP catalytic motif and an additional large C-terminal cytosolic domain ([Figure 1](#fig1){ref-type="fig"}B). Unique within this family, PRG2 bears a highly acidic stretch consisting of 20 glutamic acid residues in its C-domain ("poly-E-box"). To characterize whether the PRG2-specific poly-E-box region mediates the PTEN-PRG2 interaction, we generated a PRG2 deletion mutant lacking the poly-E-box as well as the distal C terminus (PRG2ΔC amino acids \[aa\] 1--407) ([Figure 1](#fig1){ref-type="fig"}B). Co-immunoprecipitation experiments demonstrate that the PRG2-PTEN interaction does not require the PRG2 distal C terminus ([Figure 1](#fig1){ref-type="fig"}C). However, given the likely formation of complex PRG2 multimers with different members of the PRG family at the cell surface ([Figure S1](#mmc1){ref-type="supplementary-material"} complementing [@bib66]), one cannot exclude the possibility of indirect interactions with PTEN. Therefore, the PRG2-PTEN interaction was further studied using quantitative microscale thermophoresis (MST). After optimizing the expression and purification of native 1D4-tagged PRG2 from HEK cells, the purity of the tagged PRG2 was characterized ([Figures 1](#fig1){ref-type="fig"}D and 1E). Serial dilutions of PTEN were mixed with labeled, purified PRG2-1D4. MST traces identified a dissociation constant for PRG2 binding to PTEN in the low micromolar range, demonstrating that the physical interaction between PRG2 and PTEN is of a direct nature ([Figure 1](#fig1){ref-type="fig"}F).Figure 1Interaction of PTEN with PRG2(A) Immunoprecipitation (IP) with anti-PTEN or anti-PRG2 antibodies was performed on E18 rat brain lysate and DIV 9 cortical cultures, and immunoblotted (western blot \[WB\]) with the indicated antibodies.(B) PRG2 belongs to the LPPR family of membrane proteins with six transmembrane (TM) regions. PRG2 shows close homology to PRG1 with 49% amino acid identity and 63% similarity. PRG2 contains a long hydrophilic C-terminal cytoplasmic extension with 20 glutamic acid residues ("poly-E-box"). *Prg2* full-length (aa 1--716) and *Prg2* deletion construct (PRG2ΔC, aa 1--407) were generated.(C) IP and WB studies show the independence of the PTEN-PRG2 interaction on the distal C terminus. FLAG-IPs were analyzed with the indicated antibodies.(D) Purification scheme used to isolate tagged PRG2.(E) Coomassie-stained gel and western blot showing purity and integrity of PRG2. TL, total cell lysate; SN, unbound fraction; EL, final PRG2 eluate in detergent Fos-Choline-14; EL A8-35, PRG2 in amphipol A8-35.(F) PRG2-PTEN binding measured by microscale themophoresis (MST); n = 7 replicates of two independent purifications. Plotting the ratio of pre-thermophoresis and during thermophoresis fluorescence (F~norm~) ± SD with the concomitant fitting of the data yielded a dissociation constant K~D~ of 0.73 ± 0.22 μM.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

PRG2 Alters PTEN Localization and Activity {#sec2.2}
------------------------------------------

Association of PTEN with protein complexes may control cellular responses by confining signaling events to subcellular compartments and/or by altering the PTEN phosphatase enzymatic activity. We deployed two experimental strategies to investigate the molecular framework of PRG2 action in the control of PTEN function. In the first set of experiments, we examined the possibility that PRG2 sequesters PTEN to cellular compartments, using N1E-115 neuroblastoma cells expressing *Prg2-Flag*. Overexpressed PRG2-FLAG localized to the plasma membrane and was able to redirect endogenous PTEN to the cellular periphery ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S7](#mmc1){ref-type="supplementary-material"}). In the second set of experiments, we tested whether PTEN activity was altered in the presence of PRG2 by establishing a phosphatase assay. After co-transfection of COS-7 cells with *GFP-PTEN* and control vector or *Prg2-Flag*, we measured the activity of immunoprecipitated PTEN against PI(3,4,5)P~3~ in a standard Malachite-Green-based colorimetric assay ([@bib13]). Exogenous *Prg2* expression resulted in a dose-dependent decrease in PTEN phosphatase activity ([Figure 2](#fig2){ref-type="fig"}C), whereas the expression of the *Prg2ΔC* deletion did not change PTEN activity ([Figure 2](#fig2){ref-type="fig"}D). To directly correlate PTEN activity with PTEN protein content in each treatment, we normalized the phosphate produced to relative concentrations of immunoprecipitated PTEN. This demonstrated that PRG2 can reduce PTEN activity to approximately 50% at the highest PRG2 concentration tested ([Figure 2](#fig2){ref-type="fig"}E). The specificity of this result was further verified by assaying the activity of the 5′ phosphatase SHIP2, which does not interact with PRG2 (data not shown). *Prg2* expression did not affect the amount of SHIP2-produced phosphate ([Figure 2](#fig2){ref-type="fig"}F). In conclusion, these experiments established that PRG2 is able to both direct PTEN between cell compartments and to inhibit PTEN phosphatase activity.Figure 2PRG2 Redirects PTEN to the Plasma Membrane and Inhibits PTEN's Phosphatase Activity(A) PRG2 redirects PTEN to the plasma membrane in neuroblastoma cells. Panels show *Prg2-Flag* expressing N1E-115 cells and *GFP* expressing cells immunolabeled with anti-FLAG (green) and anti-PTEN (white). Scale bar: 5 μm.(B) Quantification of membrane PTEN relative to cytosolic PTEN. Bars indicate the means ± SEM from n = 16 (GFP) and n = 13 (PRG2) cells from two independent experiments.(C and D) PRG2 decreased PTEN-activity. COS-7 cells were co-transfected with *GFP-PTEN* and control vector, or with *GFP-PTEN* and increasing amounts (μg) of *Prg2*-*Flag* (C) or *Prg2ΔC-Flag* (D). PTEN activity after IP was measured in a colorimetric assay.(E) Normalized net phosphate release. Phosphate produced (at 10 min) was normalized to relative PTEN concentration in IP. Bars indicate the mean of three experiments ± SD. ^∗∗∗^p \< 0.001 (t test)(F) PRG2 does not alter phosphate product released by the 5′ phosphatase SHIP2. Bars indicate the mean of three experiments ± SD, n.s. = not significant.

PRG2 Affects Cellular PI(3,4,5)P~3~ and F-Actin-Rich Protrusions in a PTEN-Dependent Manner {#sec2.3}
-------------------------------------------------------------------------------------------

Unlike most protein phosphatases, PTEN preferentially dephosphorylates phosphoinositide substrates. PTEN activity thus decreases levels of plasma membrane PI(3,4,5)P~3~ and functions as a growth suppressor by negatively regulating the PI3K/AKT signaling pathway. We, therefore, addressed whether the PRG2-PTEN interaction regulates PI3K/AKT signaling strength in cells. HEK293 cells were co-transfected with *GFP-PTEN* and *Prg2-Flag*/*Prg2-ΔC-Flag*. To monitor subtle changes in PI3K/AKT activity in transfected cells only, the co-transfection of *AKT-GFP* was exploited as an effective and sensitive experimental protocol ([@bib2]). In these experiments, intact PRG2, but not the C-terminal PRG2-truncated protein missing the poly-E-box (PRG2ΔC), antagonized PTEN's ability to reduce pAKT ([Figures 3](#fig3){ref-type="fig"}A and 3B).Figure 3PRG2 Regulates pAKT and PI(3,4,5)P~3~ in Dependence of PTEN(A) PRG2 rescues decreased pAKT-levels induced by *PTEN* overexpression. HEK293 cells were triple transfected with *AKT-GFP*, *GFP-PTEN* (or control vector), and *Prg2-Flag/Prg2ΔC-Flag* (or control vector). Cell lysates were analyzed with indicated antibodies.(B) Bars represent normalized pAKT(S473) over total AKT ratios across treatments ± SEM of n = 5 independent experiments. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (one-way ANOVA with Bonferroni post hoc test).(C) PRG2 rescues the loss of PI(3,4,5)P~3~-accumulations induced by *PTEN* overexpression. U87MG cells transfected with *PH-AKT-mRFP* (red) and *GFP*, *GFP-PTEN*^*C124S*^, *GFP-PTEN* (green, insets), and *Prg2-Flag* (white, insets). Panels show single confocal sections. Arrowheads indicate PH-AKT foci at plasma membranes (PM). Scale bar: 10 μm.(D) Cells were scored for the presence of peripheral PH-AKT foci. Bars show the means ± SD of two independent experiments performed in duplicate, n ≥ 50. ^∗∗^p \< 0.01 (t test).(E) PRG2 protects from the loss of peripheral F-actin accumulations induced by *PTEN* overexpression. Cells were stained with Phalloidin (F-actin, red top panels), anti-GFP (for detection of GFP or GFP-PTEN, green bottom panels) and anti-FLAG antibodies (for detection of PRG2-FLAG or PRG2ΔC-FLAG, white insets in lower magnification). Panels show maximum intensity confocal projections. Arrowheads indicate peripheral F-actin foci. Scale bar: 10 μm.(F) Cells were scored for presence of peripheral F-actin foci. Bars show means ± SD of three independent experiments performed in duplicates, n ≥ 60. ^∗∗^p \< 0.01 (t test).

In a direct approach to characterize possible regulation of plasma membrane PI(3,4,5)P~3~, by PRG2, we performed a pleckstrin homology (PH)-domain translocation assay in *PTEN*-deficient U87MG glioblastoma cells ([@bib43]). Under basal conditions, the PI(3,4,5)P~3~-binding AKT PH-domain was found to sporadically enrich at the plasma membrane in U87MG cells expressing control *GFP* or catalytically inactive *GFP-PTEN*^*C124S*^. PH-domain membrane recruitment was significantly reduced after expression of catalytically active *GFP-PTEN* ([Figure 3](#fig3){ref-type="fig"}C). In contrast, co-expression of *Prg2* with *PTEN* antagonized the PTEN effect on PH-AKT accumulation ([Figures 3](#fig3){ref-type="fig"}C and 3D). These results indicate that PRG2 is able to antagonize the PI(3,4,5)P~3~-hydrolyzing activity of PTEN in cells.

U87MG cells are highly migratory cells that extend dynamic F-actin-rich protrusions ([Figure 3](#fig3){ref-type="fig"}E). Given the established function of PI(3,4,5)P~3~ to drive spontaneous cytoskeletal and membrane dynamics, we examined the effect of the PRG2-PTEN interaction on the actin cytoskeletal network in U87MG cells. Control transfected cells maintain robust F-actin protrusions, which remain unaffected by expression of *Prg2* ([Figures 3](#fig3){ref-type="fig"}E and 3F). As expected, *PTEN* expression resulted in a decreased percentage of cells exhibiting F-actin-enriched membrane protrusions, confirming the validity of this assay. Co-expression of full-length *Prg2* with *PTEN* antagonized the PTEN-induced decrease in membrane protrusions, whereas the *Prg2-*deletion mutant missing the poly-E-box (PRG2ΔC) failed to rescue the PTEN effect ([Figure 3](#fig3){ref-type="fig"}F). Collectively, these results establish a causal link for PRG2 as a positive regulator of both membrane PI(3,4,5)P~3~ and F-actin, in dependency on PTEN. They further demonstrate the ability of PRG2 to protect PI(3,4,5)P~3~ from PTEN hydrolysis.

PRG2 Expression Correlates with Growth and Branching of Axons and Dendrites {#sec2.4}
---------------------------------------------------------------------------

Next, we determined the pattern of *Prg2* expression at different stages in the developing rodent brain using a custom-made anti-PRG2 antibody. This antibody is specific for detecting PRG2 by western blotting and immunocytochemistry because reductions in *Prg2* expression accurately reproduced the decrease in protein abundance in both experimental paradigms ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Analyses of the expression of PRG2 protein in rat brain lysates obtained at different developmental (E13--E19) and postnatal/adult stages (P1--W40) revealed high protein expression during stages corresponding broadly to cortical migration and branch formation of axon projections (E17--P1; [Figure 4](#fig4){ref-type="fig"}A). In contrast, the related PRG1 was first detected, albeit weakly, at P1, and its expression peaks at P15. Western blotting of different brain regions (cortex, hippocampus, cerebellum) with the anti-PRG2 antibody confirmed dynamic expression with high PRG2 levels found at young postnatal stages, whereas embryonic or late postnatal/adult stages show less PRG2 abundance ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Immunohistochemistry using the anti-PRG2 antibody on mouse brain sections identified expression of the protein in the cortical plate and in axonal tracts at E16.5 ([Figure 4](#fig4){ref-type="fig"}B). Cortical neurons cultured *in vitro* demonstrated a steep increase in the expression of PRG2 protein between DIV 3 and 5 in culture, which coincide with a general phase of complex neuronal branch behavior of axonal and dendritic processes ([Figure 4](#fig4){ref-type="fig"}C). Indeed, our direct analyses of axon morphogenesis in time identified that the steepest increase in axon branch growth occurs after DIV3 ([Figure S3](#mmc1){ref-type="supplementary-material"}B). The control of the dynamic expression of *Prg2* most likely occurs at the level of the protein because analyses of mRNA expression at different stages revealed high, relatively constant mRNA levels throughout DIV1--DIV6; in sharp contrast, *Prg1* mRNA levels were initially low but increased significantly at later stages ([Figure S3](#mmc1){ref-type="supplementary-material"}C).Figure 4Profile of Developmental Expression in the Forebrain and Subcellular Distribution of PRG2 in Neurons(A) *Prg2* expression *in vivo* peaks at birth. Rat brain lysates isolated at different developmental stages were analyzed by WB using the indicated antibodies. E, embryonic day; P, postnatal day; W, weeks. *Prg2* and *Prg1* expression was quantified at three time points from five independent animals. Bars represent protein levels relative to tubulin ± SEM. ^∗∗∗^p \< 0.001, n.s. = not significant (one-way ANOVA with Bonferroni post hoc test).(B) Coronal sections through the mouse forebrain at E16.5 labeled with anti-L1 and anti-PRG2 antibodies show axonal localization of PRG2. Nuclei were visualized by Hoechst. Scale bar: 200 μm.(C) *Prg2* expression in primary neurons. PRG2 and PTEN levels in cortical neurons at different days in vitro (DIV) analyzed by WB.(D) Subcellular distribution of PRG2 in hippocampal neurons cultured for 9 DIV and stained with anti-MAP2, anti-PRG2, and Phalloidin (F-actin). A single, confocal section at high magnification reveals punctate labeling of PRG2 at the membrane of axons. Scale bar: 2 μm. PRG2 membrane enrichment was measured as a percentage of processes with plasma-membrane-enriched PRG2 and the ratio of cell edge to middle intensity. Results are means ± SEM of 21 (axonal) and 27 (dendritic) measurements from 12 axonal and dendritic processes. ^∗∗∗^p \< 0.001 (t test).(E) Structured illumination microscopy (SIM) of PRG2 and F-actin in 9 DIV hippocampal neurons. Cells were stained with anti-PRG2 antibody and Phalloidin. Single sections show regular PRG2 puncta at the plasma membrane. Scale bar: 0.5 μm.(F) SIM of 9 DIV hippocampal neurons treated with 5 μm latrunculin B for 1 h or 3 h and labeled with anti-Tau and anti-PRG2 antibodies. Scale bar: 1 μm. Bar graph demonstrates the increase in mean distance between two consecutive PRG2 spots following latrunculin B treatment. Results are means ± SEM from n = 9 neurons per condition, with ≥10 μm axon lengths per neuron analyzed. ^∗∗∗^p \< 0.001 (one-way ANOVA with Bonferroni post hoc test).See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

We then investigated the endogenous distribution of PRG2 in neurons and identified membrane localization of PRG2 in hippocampal neurons cultured for 9 days *in vitro*. The presence of prominent PRG2 puncta at the plasma membrane, predominantly in axons, was striking, whereas most dendrites showed intracellular PRG2 localization ([Figures 4](#fig4){ref-type="fig"}D and [S7](#mmc1){ref-type="supplementary-material"}B). To further characterize the axonal PRG2 distribution, we imaged neurons using three-dimensional structured illumination microscopy (3D-SIM), a super-resolution imaging method that reaches a 2-fold increase in axial and lateral resolution compared with conventional confocal microscopy ([@bib19], [@bib46]). Membrane-localized PRG2 adopted a regular pattern along the axon with a periodicity of approximately 300 nm ([Figures 4](#fig4){ref-type="fig"}E, 4F, and [S7](#mmc1){ref-type="supplementary-material"}D--S7F for quantification). The periodic distribution of PRG2 does not correlate with F-actin ring-like structures that wrap around the circumference of axons ([@bib64]), which are evenly spaced along the axon shaft approximately every 190 nm ([Figure 4](#fig4){ref-type="fig"}E). However, depolymerizing actin filaments altered the periodicity of PRG2 clusters, indicating that PRG2 nanoscale localization on the axonal plasma membrane is regulated by F-actin ([Figures 4](#fig4){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}C--S2E). Interestingly, although both short (1 h) and long (3 h) treatment with latrunculin B resulted in broader distance distributions of axonal PRG2 puncta, only long-term treatment caused a net decrease in plasma membrane PRG2 ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Control experiments supported both treatments as preserving overall normal morphologies ([Figure S2](#mmc1){ref-type="supplementary-material"}C). This, together with the results shown in [Figure 3](#fig3){ref-type="fig"}, suggests a reciprocal relationship for PRG2 and the F-actin cytoskeleton. In summary, these experiments establish PRG2 as a neuronal plasma membrane protein, which---through the interaction and inhibition of PTEN---may facilitate signaling processes that are confined to sub-micrometer-sized clusters at the axon cell membrane.

PRG2 Induces Filopodia and Branches in ESC-Derived Neurons {#sec2.5}
----------------------------------------------------------

Several PRG membrane proteins have previously been shown to control neuronal growth responses, such as filopodia formation, as well as axon growth and guidance after CNS lesions ([@bib4], [@bib16], [@bib45], [@bib61]). When overexpressed, PRG family members are distributed to the plasma membrane and induce the formation of filopodia ([@bib5], [@bib61], [@bib66]). Here, we confirmed this to be the case: overexpression of *Prg2* in N1E-115 cells results in a strong induction of filopodia with a characteristic punctate distribution of PRG2 revealed by SIM ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). Given the prominent localization of PRG2 in axons, we tested the possibility that PRG2 may cooperate with PTEN during the generation of axon filopodia in neurons. For this, we used embryonic stem cell (ESC)-derived motor neurons (ESCMNs), which can rapidly enter a robust axonal growth phase. Importantly, young ESCMNs do not express detectable *Prg2* at these early phases of rapid growth ([Figure 5](#fig5){ref-type="fig"}A). We generated doxycycline-inducible cell lines expressing *Prg2* after neural differentiation into embryoid bodies. We then re-plated doxycycline-induced (or non-induced) ESCMNs at low density and assessed neuronal morphologies after 2 h (or after 24 h for subsequent experiments when branching was analyzed) ([Figure 5](#fig5){ref-type="fig"}B). ESCMN-*Prg2-Flag* clones responded to induction of *Prg2* expression with a significant increase in the number of filopodia ([Figures 5](#fig5){ref-type="fig"}C and 5D). Interestingly, filopodia induction was confined to the axon compartment and not seen around neuronal cell soma or growth cones (data not shown).Figure 5*Prg2* Overexpression in ES-Cell-Derived Neurons Induces Axon Filopodia Involving PI3K/PI(3,4,5)P~3~(A) Induction of *Prg2-Flag* expression after doxycycline (DOX) application. Lysates of ES-cell-derived motor neurons (ESCMNs) treated with 2 μg/mL doxycycline for 24 h were analyzed using the indicated antibodies.(B) ESCMN culture scheme.(C) Images show representative examples of neurons stained with Phalloidin (F-actin) after *Prg2* induction with or without the PI3K inhibitor LY294002 (15 μM, 2 h). Scale bar: 10 μm. Doxycycline-induced *Prg2* expression results in an increase in the number of axon filopodia. The PRG2-induced effect is reversed by PI3K inhibition using LY294002.(D) Quantification of filopodia. Bars show the mean number of filopodia per neuron, and the average length of filopodia/neuron ± SEM of 2--3 independent experiments performed in triplicates, n ≥ 100. \*\*p \< 0.01, ^∗∗∗^p \< 0.001 (one-way ANOVA with Bonferroni post hoc test).(E) *Prg2-*induced ESCMNs cultured for 24 h in the presence or absence of LY294002 (15 μM). PRG2 increases the number of axons and axon branches in dependence of PI3K/PI(3,4,5)P~3~. Cells were stained with anti-tubulin antibody (green) and Phalloidin (red). Scale bar: 30 μm.(F) Quantification of axons per cell and axonal branching. Bars show the mean number of branches ± SEM of two to three independent experiments performed in triplicates, n ≥ 120. ∗∗p \< 0.01, ^∗∗∗^p \< 0.001 (one-way ANOVA with Bonferroni post hoc test).See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Filopodia are dynamic membrane extensions generated by bundles of F-actin that are essential for numerous cellular processes involved in the establishment of neuronal morphology ([@bib21]). Axon filopodia are thought to initiate the formation of collateral branches and synaptic structures and arise from specialized cytoskeletal structures termed F-actin patches ([@bib28], [@bib34]). Because PI(3,4,5)P~3~ has been shown to drive the formation of axonal F-actin patches, filopodia, and axon branches ([@bib29], [@bib54]), we asked whether PRG2-induced axon filopodia are sensitive to PI3K/PI(3,4,5)P~3~ inhibition. To test that idea, we applied the PI3K inhibitor LY294002 immediately after re-plating the ESCMNs following *Prg2* induction with doxycycline. Quantification of filopodia revealed a PI3K signaling dependency for the PRG2-induced number of filopodia ([Figure 5](#fig5){ref-type="fig"}D). Interestingly, *Prg2* induction did not affect the average length of filopodia per neuron, suggesting that PRG2 is involved in initiating filopodia, rather than influencing the filopodia growth phase ([Figures 5](#fig5){ref-type="fig"}C and 5D).

We also tested the effect of induction of *Prg2* expression in ESCMN-*Prg2-Flag* clones on axon branching ([Figure 5](#fig5){ref-type="fig"}E). After incubation of cells for 24 h, we found a significant increase in both the number of axons extending from a single neuronal soma as well as in the number of axon branches in cultures treated with doxycycline ([Figures 5](#fig5){ref-type="fig"}E and 5F). In the presence of the PI3K inhibitor, the axon phenotype was again reversed to that in untreated controls. Together, these results provide evidence for a requirement of PI(3,4,5)P~3~ in PRG2-induced axon filopodia formation and indicate PI(3,4,5)P~3~ as an essential signaling component of PRG2 function. Given the identified association of PTEN and PRG2 causing inhibition of the phosphatase, the protein interaction is likely involved in stabilizing phosphoinositides within axon membrane compartments required for filopodia and branch formation.

PRG2 Redistributes Growth by Controlling Axon Branching Morphogenesis {#sec2.6}
---------------------------------------------------------------------

To directly examine the role of PRG2 in axon morphogenesis and branching, we performed *in vitro* experiments using neurons from wild-type (WT) and *Prg2* knockout (*Prg2*^−/−^) mice. *Prg2*^−/−^ were established through CRISPR/Cas9-mediated excision of the first exon in the *Prg2* gene ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}). *Prg2*^−/−^ mice were backcrossed to wild-type Bl6/N for several generations. As a result of homozygosity for the null allele, the PRG2 protein was not detected by western blotting ([Figure 6](#fig6){ref-type="fig"}A). Hippocampal neurons of WT and *Prg2*^−/−^ mice were dissociated, and axon morphology was analyzed at different developmental stages. In the first set of experiments, after *in vitro* culture for 1 day, neurons had clearly adopted early polarized (stage 3) morphologies. Quantification revealed that PRG2 loss did not affect early neuronal growth and polarization ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C) but led to significant decreases in the density of axon filopodia compared with controls, again without affecting filopodia length ([Figures 6](#fig6){ref-type="fig"}B and 6C).Figure 6PRG2 Is Required for Filopodia and Branch Formation in Axons(A) Validation of *Prg2* knockout (*Prg2*^−/−^) mouse by WB using P8 brain lysates.(B) Hippocampal neurons from WT or *Prg2*^−/−^ mice imaged at 1.5 DIV. Scale bar: 20 μm.(C) Bars show the mean number of filopodia per axon length, the mean length of filopodia, and the mean length of the longest filopodium/neuron ± SEM of four independent experiments, n ≥ 100. ^∗∗∗^p \< 0.001 (t test).(D) Hippocampal neurons from WT or *Prg2*^−/−^ mice imaged at 5 DIV. Scale bar: 50 μm.(E) Bar graphs show mean ± SEM of 3 independent experiments, n ≥ 100. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001 (t test).(F) Schematic representation of *Prg2*^−/−^ neuronal growth at two developmental stages.(G) Correlation of branches and total axon length. Transparent dots represent individual neurons of either WT (blue) or *Prg2*^−/−^ (red); darker dots represent means for equal clusters of neurons to reduce the complexity of the dataset.(H) Representative filopodium emerging from a local PRG2 spot. Panels show F-actin probe GFP-Utrophin and Halo-tagged PRG2 over 40 s in 16-color Look-Up Table (LUT; FIJI), scale bar: 2 μm.(I) Boxplots of nearest-neighbor analyses show smaller distances of emerging filopodia to PRG2 clusters when compared with randomly distributed clusters. Whiskers show the 5%--95% interval, ^∗∗∗^p \< 0.001 (Wilcoxon signed rank test), n = 73 from four independent experiments.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

In a second set of experiments, we cultured neurons for 5 days to developmental stages when they adopt more complex, branched morphologies. Those experiments showed that loss of PRG2 significantly reduced overall axon branching compared to controls ([Figures 6](#fig6){ref-type="fig"}D and 6E), whereas dendrite morphology was unaffected ([Figure S6](#mmc1){ref-type="supplementary-material"}D). To exclude the possibility that this phenotype was a consequence of a general impairment in neuronal growth, we quantified axon length, as well as the length of the primary (longest) axonal process in each genotype. This analysis found that PRG2-deficient neurons showed no significant change in overall length of axonal processes in individual cells but exhibited significant increases in the length of primary axons ([Figure 6](#fig6){ref-type="fig"}E). This suggests that, through the ability to control axon branching, PRG2 may direct cell growth toward primary or collateral axons, respectively. This indeed seems to be the case: although both WT and *Prg2*^−/−^ neurons demonstrate a high degree of correlation between overall axon length and number of branches, *Prg2*^−/−^ neurons show a decreased probability of branching with increased axon length ([Figures 6](#fig6){ref-type="fig"}F and 6G).

To address the specific regulatory role of PRG2 during formation of filopodia in neuronal axons, a core process of axon branch formation, we exploited live cell imaging of tagged PRG2 in *Prg2*^−/−^ neurons. We expressed *Halo-Prg2* in combination with the F-actin probe GFP-Utrophin and noticed a consistent co-localization (73%) of newly extending filopodia with their described precursors, F-actin patches. Interestingly, Halo-PRG2 showed a punctate pattern along the axon ([Figure 6](#fig6){ref-type="fig"}H). Although PRG2 enrichment did not predict a site of *de novo* filopodia formation, per se, 55% of filopodia emerged directly from PRG2 clusters and 33% within the vicinity of PRG2 clusters. To exclude the possibility that filopodia emerging from PRG2 clusters as random events, we developed a semi-automatic nearest-neighbor analysis of emerging filopodia. Filopodia were found to form preferentially in proximity (\<1 μm) to intensity maxima of PRG2 when compared with the same number of randomly distributed spots ([Figures 6](#fig6){ref-type="fig"}I and [S6](#mmc1){ref-type="supplementary-material"}E). Our combined results identify that PRG2 clusters are able to locally induce filopodia to facilitate axon branch formation.

The Effect of PRG2 on Axon Branching Morphogenesis Involves PTEN {#sec2.7}
----------------------------------------------------------------

In the final set of experiments, we tested whether the PRG2 effect on branching involves the function of PTEN. We used *Pten* small hairpin (shRNA) virus particles to test epistasis between PRG2 and PTEN in *Prg2*^−/−^ neurons cultured for 5 days ([Figures 7](#fig7){ref-type="fig"}A and 7B). PTEN inhibition did not significantly alter overall axon length in either WT or *Prg2*^−/−^ neurons ([Figure 7](#fig7){ref-type="fig"}C). However, knockdown of *Pten* reversed the increase in primary axon length and also corrected the deficit in axon branch number induced by *Prg2*^−/−^ ([Figure 7](#fig7){ref-type="fig"}C), suggesting that PTEN indeed cooperates with PRG2 during axon branching. To test that idea further, we compared the ability of full-length PRG2 to restore branching in *Prg2*^−/−^ neurons, with that of the PRG2 tail deletion (PRG2ΔC) that is unable to inhibit PTEN ([Figure 7](#fig7){ref-type="fig"}D). Although full-length PRG2 rescued branching in *Prg2*^−/−^ neurons, the PRG2ΔC mutant failed to do so ([Figures 7](#fig7){ref-type="fig"}E and 7F), which indicates that PRG2's involvement during axon branching depends on its ability to antagonize PTEN activity. Given its specific upregulation at developmental stages coinciding with branching morphogenesis, we propose that PRG2 functions as an efficient internal "off" switch for the PTEN-mediated hydrolysis of PI(3,4,5)P~3~ essential for establishing and segregating membrane phosphoinositides required for axon branching in hippocampal neurons.Figure 7PTEN Cooperates with PRG2 during Branch Formation(A) Scheme of experiments.(B) Validation of shRNA specificity to target *Pten*.(C) Knockdown of *Pten* rescues branching deficit of *Prg2*^−/−^ neurons at 5 DIV. Bar graphs show mean total axon length, mean primary axon length, and mean branches per axon length ± SEM of five independent experiments, n ≥ 130. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001 (one-way ANOVA with Bonferroni post hoc test).(D) Validation of viral expression of *Prg2-Flag* or *Prg2ΔC-Flag* by WB.(E) Hippocampal *Prg2*^−/−^ neurons expressing *Prg2-Flag* or *Prg2ΔC-Flag* imaged at 5 DIV. Scale bar: 50 μm.(F) PRG2-FLAG (but not PRG2ΔC-FLAG) increases branch density in *Prg2*^−/−^ neurons. Bars show mean total axon length and mean branches per axon length ± SEM of 88--97 cells per condition from four independent cultures. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (one-way ANOVA with Bonferroni post hoc test).

Discussion {#sec3}
==========

Here, we uncover a role for the membrane protein PRG2 in axon branch growth, via the regulation of PTEN localization and activity. We identify PI(3,4,5)P~3~ as a critical signaling molecule for PRG2 function and establish its importance in mediating PRG2 effects on actin cytoskeleton organization and filopodia generation. Our results indicate that PRG2 is temporally and locally poised to inhibit global growth suppression mediated by PTEN. In principle, PRG2 control of PTEN allows the introduction of a PI(3,4,5)P~3~ amplification system that may instruct cytoskeletal organization in controlling neuronal growth behavior.

Spatiotemporal Control of PI(3,4,5)P~3~ by PRG2 {#sec3.1}
-----------------------------------------------

Recent studies suggest a common mechanistic step in initiating nanoscale membrane protrusions in close apposition with F-actin accumulations as a filopodia initiation mechanism in both axons and dendrites ([@bib23], [@bib29], [@bib44]). These filopodia-initiating steps have been shown to require the presence of local PI(4,5)P~2~ and/or PI3K products PI(3,4,5)P~3~ and PI(3,4)P~2~ at plasma membranes, to recruit and regulate proteins involved in sensing membrane curvature and/or orchestrating F-actin nucleation and assembly ([@bib29], [@bib44], [@bib67]). It is still unclear whether a mechanism exists to mark "competent" plasma-membrane micro-domains for initiation of these early events. Moreover, whether membrane proteins per se are involved in this activity has yet to be elucidated.

To date, only a few membrane proteins, including members of the PRG family, have been linked to filopodia and neurite or branch formation in neurons and other cells ([@bib5], [@bib11], [@bib35], [@bib51], [@bib61], [@bib66]). At least one member of the family, PRG3 (LPPR1), has been shown to promote axonal growth after injury ([@bib6], [@bib16]), suggesting that PRGs---in general---may boost intrinsic growth capacity in neurons. In this study, we present evidence for additional functions of PRGs in orchestrating axon branching during development. We demonstrate that an axonal membrane complex consisting of the transmembrane protein PRG2 and PTEN organizes the complex branching behavior of neurons. In this way, gain-of-function and loss-of-function of PRG2 results in increases and decreases, respectively, in axon filopodia and branch numbers in neurons. This mechanism likely involves local accumulations of PRG2 that instruct emerging filopodia to form branches and the ability to antagonize PTEN. In molecular terms, PRG2 recruits PTEN and inhibits its PI(3,4,5)P~3~ phosphatase activity, thus resulting in local stabilization of PI(3,4,5)P~3~ at the plasma membrane. Unlike upstream activation of PI3K by growth factors, disinhibition of PTEN would suggest milder phenotypes in downstream signaling. This model implies the presence of altered dynamics and/or lower abundance of microscale PI(3,4,5)P~3~ domains along the axonal membrane as a result of the *Prg2* deletion. We have extensively analyzed PI(3,4,5)P~3~ domains along the axonal membrane with PH-domain probes and anti-PI(3,4,5)P~3~ antibodies, combined with pharmacological or genetic approaches (J.F., G.L., and B.J.E., unpublished data). However, the low sensitivity and low dynamic range afforded by these approaches, together with the inherent difficulties associated with small-diameter axons in hippocampal neurons and the stabilization of PI(3,4,5)P~3~ by high-affinity PH domain probes ([@bib65]) have precluded us from quantifying reliable and consistent changes in PI(3,4,5)P~3~-rich domains in PRG2-deficient axons. Nevertheless, the fact that PRG2-dependent alterations in the filopodia and branching capacity of neurons are reversed by correcting PI(3,4,5)P~3~ levels via PI3K or PTEN activity provides a strong argument for PI(3,4,5)P~3~ as a critical signaling component of PRG2 function along the neuronal axon.

PRG2 Regulates Axonal F-Actin Cytoskeleton and Induces Filopodia {#sec3.2}
----------------------------------------------------------------

Integration of neurons into functional circuits requires both robust formation as well as flexible remodeling of their morphology. This complex regulation involves multiple pathways, including phosphoinositides, calcium and Rho-family GTPases (reviewed in [@bib17], [@bib28]) to instruct the formation of dynamic F-actin-rich structures that are commonly stabilized by microtubule to mature into specialized compartments, such as branches ([@bib14]). Our studies show that, in addition to regulating PTEN localization and activity, PRG2 is highly likely to impose additional and complementary mechanisms for controlling local F-actin remodeling along the axon to regulate branching. First, PRG2 exhibits a striking localization pattern of sub-micrometer size clusters along the axonal membrane. Its periodic localization, revealed by super-resolution is controlled by axonal F-actin, as suggested by latrunculin experiments. Second, PRG2 has recently been found to interact with, and to activate, radixin ([@bib9]). Radixin, an ERM family protein, crosslinks F-actin to the plasma membrane and has been shown to stabilize membrane protrusions in neuronal growth cones ([@bib42]). Although the PRG2-radixin interaction was studied in the context of lysophosphatidic acid (LPA)-induced growth cone guidance in thalamocortical neurons ([@bib9]), it is possible that a similar mechanism may operate along the axon shaft. Indeed, our live cell imaging identified F-actin rearrangements---specifically during the formation of filopodia---to occur preferentially in the vicinity of PRG2 clusters along the axon.

PRGs Partake in Dynamic Axonal Scaffolds {#sec3.3}
----------------------------------------

An additional mode of functioning for PRGs is suggested by their ability to form multimeric complexes ([@bib66]). We have verified the existence of heteromeric PRG2 complexes at the plasma membrane. It is highly likely that PRG2-PTEN complexes that include different PRGs exert non-redundant functions in neuronal axon growth at distinct developmental stages. Several PRGs exhibit partially overlapping expression patterns in the developing brain ([@bib62]). Notably, PRG3, but not PRG5 or PRG1, is enriched in developing axons ([@bib61]) and has been proposed to promote axonal growth and sprouting after injury ([@bib6], [@bib16]). Thus, although we have extensively characterized the effects of PRG2 loss in developing neurons *in vitro*, it is likely that the robust regulation of neuronal branching, as well as redundancy within the PRG family, will dampen gross differences in neuronal morphology of *Prg2*^−/−^ mice *in vivo*.

Local Inhibition of Global PTEN {#sec3.4}
-------------------------------

In neurons, PTEN appears to be active and dynamically interacting with the plasma membrane in a constitutive manner ([@bib60]), contributing as gatekeeper to limiting basal levels of PI(3,4,5)P~3~ and thus also preventing aberrant formation of branches during early development ([@bib31], [@bib52]). In addition to constitutive dynamic interactions with the plasma membrane, PTEN can be actively recruited by membrane PDZ-domain proteins ([@bib58]) or other transmembrane proteins and receptors ([@bib31], [@bib33]). In most cases, these enhanced membrane interactions of PTEN appear to prime PTEN activity toward PI(3,4,5)P~3~ and, thus, to antagonize PI3K signaling in a spatial manner ([@bib33]). Nevertheless, mechanisms that inhibit PTEN are thought necessary to control against silencing of PI(3,4,5)P~3~ by abundant unrestricted access of PTEN to the plasma membrane ([@bib31]).

This would be particularly relevant when steep gradients of PI(3,4,5)P~3~/PI(3,4)P~2~ are needed along the plasma membrane for initiation of neurites or filopodia/branch outgrowth. In axons specifically, PTEN is abundant and active during both embryonic development and in the adult ([@bib8], [@bib10]), and local inhibition counteracts its growth-restricting function ([@bib15], [@bib68]). In this way, a developmentally regulated, membrane-associated PRG2-PTEN complex at the axonal membrane provides an efficient intrinsic factor that is interposed to restrict PTEN activity in axons. Consistent with this, the primary phenotype of our PRG2 gain-of-function and loss-of-function experiments was restricted to axon filopodia and branches with virtually absent effects in dendrites.

This control mechanism likely operates in concert with extrinsic factors, including growth factors, such as brain-derived neurotrophic factors (BDNFs) and nerve growth factors (NGFs) that activate upstream PI3K signaling ([@bib29]), thus creating PI(3,4,5)P~3~ "hotspots" along the axonal membrane that are, in turn, stabilized or even enhanced by local PRG2-mediated PTEN inhibition. These PI(3,4,5)P~3~ hotspots are instrumental for controlling local F-actin cytoskeleton reorganization ([@bib27]), via recruitment of small GTPases of the Rho family and F-actin regulators ([@bib29], [@bib53]), toward the formation of filopodia and branches ([@bib3]). This way, the mechanism we describe adds an additional layer of precise spatial and temporal control to axon morphogenesis.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**rabbit anti PRG2, custom made, anti: CAESYYRRMQARRYQDEurogentecN/Arabbit anti-PRG1R&D SystemsCat\#MAB2874; RRID:[AB_2138597](nif-antibody:AB_2138597){#interref90}Rabbit anti-PTENCell signalingCat\#9559; RRID:[AB_390810](nif-antibody:AB_390810){#interref95}rabbit anti-AKTCell signalingCat\#9272; RRID:[AB_329827](nif-antibody:AB_329827){#interref100}rabbit anti-pSer473AKTCell signalingCat\#4060; RRID:[AB_2315049](nif-antibody:AB_2315049){#interref105}Goat anti-PTEN (N19)Santa Cruz BiotechCat\#sc-6818; RRID:[AB_654895](nif-antibody:AB_654895){#interref110}mouse anti human CD14 (clone 26ic)ATCCCat\#HB-246; RRID:[AB_2782995](nif-antibody:AB_2782995){#interref115}**Chemicals, Peptides, and Recombinant Proteins**di-C8-PI(3,4,5)P~3~Echelon BiosciencesCat\#P-3908di-C8-PI(4,5)P~2~Echelon BiosciencesCat\#P-4508PTEN (GeneBank: NM_000314) Human Recombinant ProteinOriGeneCat\#TP302627Latrunculin BMilliporeCat\#42820; CAS: 76343-94-7LY294002MilliporeCat\#440202; CAS: 154447-36-6Janelia Fluor 646 HaloTag ligandPromegaCat\#GA1120Human recombinant BDNFR&D systemsCat\#248-BDRetinoic acidSigmaCat\#R2625; CAS 302-79-4Smoothened agonist (SAG)MerckCat\#566660; CAS: 364590-63-6Doxycycline (DOX)SigmaCat\#D9891; CAS: 564-25-0G418InvitrogenCat\#10131027; CAS: 49863-47-0Amphipol (A8-35)AnatraceCat\#A835Fos-Choline-14AnatraceCat\#F312**Critical Commercial Assays**MEGAshortscript T7-KitLife Tech.Cat\#AM1354mMessage mMachine KitLife Tech.Cat\#AM1344MEGAclear KitLife Tech.Cat\#AM1908Monolith Protein Labeling Kit RED-NHSNanoTemper TechnologiesCat\#MO-L001Malachite green reagentEchelon BiosciencesCat\#K-1500**Experimental Models: Cell Lines**HEK293TNBioCAT/SBICat\#LV900A-1; RRID:CVCL_UL49HEK293S GnTI-ATCCCat\#CRL-3022; RRID:CVCL_A785COS-7ATCCCat\#CRL-1651; RRID:CVCL_0224U87MGATCCCat\#HTB-14; RRID:CVCL_0022N1E-115ATCCCat\#CRL-2263; RRID:CVCL_0451Mouse embryonic fibroblasts, Neomycin-Resistant, Strain FVB, passage 3MilliporeCat\#PMEF-NLA2lox mouse ESC clone H14IG\#E3Derivative of E14Tg2a ([@bib36])N/AA2lox mouse ESC H14IG\#E3_PRG2-Flag_clone \#B3This paperN/AA2lox mouse ESC H14IG\#E3_PRG2-Flag_clone \#B4This paperN/A**Experimental Models: Organisms/Strains**Mouse: *Prg2*^−/−^: C57 Bl/6NCrl *Prg2*^−/−^This paperN/A**Oligonucleotides**sgRNA1: GTGGCCTGGTTCCGCGGTGCThis paperN/AsgRNA2: GCCGCGGGCACGGAAGGCGTThis paperN/AshRNA PTEN: CGACTTAGACTTGACCTATAT[@bib50]N/AshRNA scrambled: CAACAAGATGAAGAGCACCAA[@bib50]N/A**Recombinant DNA**pCAGGS-PRG2-FlagThis paperN/ApCAGGS-PRG2ΔC-FlagThis paperN/ApCAX-GFP-PTEN[@bib2], [@bib30]N/ApCAX-GFP-PTENC124S[@bib2], [@bib30]N/AmRFP-PH-Akt[@bib25]N/ApCMV-GFP-Akt[@bib2], [@bib30]N/Ap2Lox-PRG2-FlagThis paperN/ApX330[@bib12]Addgene plasmid \#42230pCA-Halo-PRG2This paperN/AGFP-Utrophin(CH)[@bib7]Addgene plasmid \#26737f(syn)-NLS-RFP\_(U6)shPTENThis paperN/Af(syn)-NLS-RFP\_(U6)shCTRLThis paperN/Af(CAG)-PRG2-Flag-wThis paperN/Af(CAG)-PRG2ΔC-Flag-wThis paperN/A**Software and Algorithms**FIJI (ImageJ 1.51n)[@bib47]<https://imagej.net/Fiji>GraphPad Prism 5GraphPad Software, La Jolla, USA<https://www.graphpad.com>NeuronJ (version 1.4.3)[@bib40]<https://imagescience.org/meijering/software/neuronj/>Imaris x64 (version 8.1.2)Bitplane AG<https://imaris.oxinst.com>MO.Affinity Analysis v2.3NanoTemper Technologies<https://nanotempertech.com/>Timelapse nearest neighbor analysisThis paper<https://github.com/ngimber/NearestNeighborWorkflow_Filopodia>**Other**Monolith NT. 115 Series Standard Treated CapillariesNanoTemper TechnologiesCat\#MO-K002High-precision \#1.5 coverslipsCarl RothCat\#LH24.1VectashieldVector LaboratoriesCat\#H1000100 nm fluorescent beads (Tetraspeck)Thermo Fischer ScientificCat\#T7284

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

All unique/stable reagents generated in this study are available from the Lead Contact without restriction. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Britta Eickholt (<britta.eickholt@charite.de>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animal procedures {#sec4.3.1}

All animal procedures were conducted in accordance with local ethical guidelines and approved animal care protocols. Experiments were carried out according to the institutional guidelines of the animal welfare of the Charité Universitätsmedizin Berlin, under the licenses T0347/11 of the Landesamt for Gesundheit and Soziales Berlin (LaGeSo). All mice were maintained in a C57 Bl6/NCrl background and kept under standard conditions in a 12 hours day-night-cycle with water and food available *ad libitum*. Experiments were performed with animals of both sexes.

### Cell lines {#sec4.3.2}

HEK293TN (female), HEK293S GnTI^-^ (female), COS-7 (male), U87MG (male) and N1E-115 cells (male) were purchased from ATCC and cultured in DMEM-high glucose with GlutaMAX, 10% FCS, and 1% penicillin/streptomycin (Invitrogen) at 5% CO~2~ and 37°C. A2lox mouse ESC clone H14IG\#E3 ([@bib36]) was cultured on mitomycin-C-treated mouse embryonic fibroblasts (PMEFNL, Millipore) in knockout DMEM medium (Invitrogen) supplemented with 15% FBS (Hyclone), 1% non-essential amino acids (NEAA; Invitrogen), 2 mM L-glutamine (Invitrogen), 10 nM PD173074 (FGF/VEGF receptor tyrosine kinase inhibitor; Tocris Scientific), 0.1 mM 2-mercaptoethanol (Sigma), 1:500 dilution of LIF supernatant, 1% EmbryoMax ESCell Qualified Nucleosides (Millipore), 5 μg/ml plasmocin (Invivogen) and 1% penicillin/streptomycin (Invitrogen).

Method Details {#sec4.4}
--------------

### CRISPR/Cas9-mediated generation of Prg2 −/− mice {#sec4.4.1}

*Prg2 −/−* were generated using CRISPR/Cas9 mediated non-homologous end-joining (NHEJ). Six sgRNAs targeting non-coding regions 5′ and 3′ of exon 1 were designed and cloned into the plasmid pX330 (a gift from Feng Zhang ([@bib12]), Addgene plasmid \#42230). Efficiency of the sgRNAs was tested *in vitro* using a plasmid containing overlapping parts of *eGFP* cDNA ([@bib38]) spaced by the genomic target region of *Prg2*. Efficient sgRNA targeting induces homologous recombination of *GFP* cDNA and was monitored by fluorescence microscopy and western blot. The most efficient sgRNAs with the least predicted off-targets (determined by Tools from Sanger (<https://www.sanger.ac.uk/htgt/wge/>) and Feng Zhang's lab (<http://zlab.bio/guide-design-resources>) were used in further experiments. *In vitro* transcribed sgRNAs (MEGAshortscript T7-Kit, AM1354, Life Tech.) and *Cas9* mRNA (mMessage mMachine Kit, AM1344, Life Tech.) were purified (MEGAclear Kit, AM1908, Life Tech.) and subjected to CRISPR/Cas9 gene editing in single-cell zygotes by the Transgenic Technology Core Unit of the Charité -- Universitätsmedizin Berlin, Germany. Offspring were genotyped by PCR and sequenced using primers 5′ and 3′ of exon 1 outside the sgRNA PAM sequence ([Figure S5](#mmc1){ref-type="supplementary-material"}). NHEJ resulted in a deletion of exon 1 that led to loss of *Prg2* expression. *Prg2 −/−* mice were backcrossed to WT Bl6/N for several generations.

### Generation of PRG2 ESCMNs {#sec4.4.2}

Doxycycline-inducible *Prg2-Flag* expressing-motor neurons were established from a transgenic A2lox mouse ESC line (clone H14IG\#E3), which allows insertion of doxycycline-inducible genes by Cre/loxP-mediated cassette exchange. This parental ESC line also contains a motor neuron-specific reporter transgene (Hb9::CD14-IRES-GFP transgene) ([@bib36]). *Prg2-Flag* was subcloned into a p2Lox plasmid and after electroporation of parental ESC cells, positive clones were grown on G418-resistant mitomycin C-treated mouse embryonic fibroblasts and selected by 350 μg/ml G418 (Invitrogen). *Prg2-Flag* ESCs were differentiated in embryoid body cultures for 5 days, and motor neuron identity was induced by exposure to retinoic acid (1 μM) and smoothened agonist (SAG, 0.5 μM) between day 3 and day 5, as described previously ([@bib36]).

Cells were dissociated after induction of *Prg2-Flag* expression by 2 μg/mL doxycycline during the last day of differentiation. Motor neurons were isolated from mixed cultures by magnetically activated cell sorting (MACS) using a mouse antibody (clone 26ic, ATCC) raised against human CD14 ([@bib1], [@bib36]). *Prg2-Flag* motor neurons were plated on poly-lysine/laminin-coated coverslips at a density of 12,000 cells/cm^2^ for morphometric analyses and 100,000 cells/cm^2^ for biochemical experiments and incubated for indicated periods in the presence of 2 μg/mL doxycycline. As a control, motor neurons were isolated and cultured in parallel, but in the absence of doxycycline. Two representative *Prg2-Flag* ESC clones (H14IG\#E3B3 and H14IG\#E3B4) were used for axon filopodia/branch measurements and results were pooled.

### Brain tissue and neuronal culture {#sec4.4.3}

Whole rat brain tissue as well as tissue of individual brain regions were isolated at different ages from male and female Wistar rats and lysed in RIPA buffer (Sigma-Aldrich) with protease and phosphatase inhibitors ([@bib48]). Primary cortical or hippocampal neurons were dissected from male and female embryonic day 16.5 WT C57 BL/6NCrl or *Prg2 −/−* mice as described previously ([@bib59], [@bib30]). Briefly, cortices and hippocampi were isolated, extracellular matrix was degraded for 15 min with 10% Trypsin in HBSS (Life Technologies), washed with HBSS and neurons were triturated to single cells with glass pipets. Neurons were plated on poly-ornithine(15 μg/ml)-coated or poly-ornithine/laminin(20 μg/ml)-coated coverslips and cultured in Neurobasal A medium (Life Technologies) containing 2% B27 (Life Technologies), 1% penicillin/streptomycin (Life Technologies), 100 μM β-mercaptoethanol (Applichem) and 1% GlutaMAX (Life Technologies). For morphometric analyses, neurons were plated at a density of 15,000/cm^2^. For biochemical experiments, neurons were plated at a density of 80,000 cells/cm^2^. Neurons were transfected using a modified Lipofectamine or a modified calcium phosphate protocol ([@bib57]) as described previously. Briefly, for lipofection 1-1.5 μg of DNA with 1μl Lipofectamine 2000 per well (12-well-plate or 4-well Ibidi dish) were diluted in OptiMEM and incubated for 10min at 37°C. The cell culture medium was collected, replaced by transfection mix, and the cells were incubated at 37°C 5% CO2 for 20 min. After removal of the transfection mix the cells were grown in their conditioned medium for 2-3 days. For calcium phosphate transfection, 4 μg plasmid DNA per well (12-well-plate) were mixed with 250 mM CaCl~2~, then gently taken up in an equal volume of 2xBBS buffer (50 mM BES, 280 mM NaCl, 1.5 mM Na~2~HPO~4~, pH 7.26) and finally incubated in Neurobasal A medium with B27 and Glutamax for 15 min at room temperature. This transfection mix replaced the medium of primary neurons for 45 min and was washed off with washing buffer (135 mM NaCl, 4 mM KCl, 1 mM Na~2~HPO~4~, 2 mM CaCl~2~, 1 mM MgCl~2~, 20 mM HEPES, 20 mM d-Glucose, pH 7.3) before the neurons were put into their previous culture medium until further processing.

For viral transductions of cultured neurons, lentiviral vectors expressing nuclear localized RFP controlled by the human synapsin-1 promotor, and the appropriate shRNA controlled by the U6 promoter, were used. Lentiviral particles were produced by the viral core facility of the Charité -- Universitätsmedizin Berlin, Germany (<https://vcf.charite.de/en/>).

### Transfection of cell lines {#sec4.4.4}

Cell lines were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions for plasmid DNA or siRNA. For mRFP-PH-AKT translocation and F-actin foci assays, U87MG cells were plated on coverslips in 24-well plates (10,000/cm^2^) and co-transfected with the appropriate plasmids. For antibody test, increasing amounts of *siPrg2* (Thermo Fisher Scientific, ON TARGET plus SMARTpool *Prg2*: GAAGCGAGCCAGCGUGGAU, CCAGGCAGCUUAUCGGUGA, UGUCUACGUGUCGAUGUA, CCUCAAUCAUGGUCGGCGA) or ON-Target plus Non-Targeting pool (D-001810-10) was cotransfected with *GFP* or *Prg2-Flag* in HEK293 cells. For colocalization studies of PRGs or SIM of PRG2, N1E cells were plated on 12-well coverslips or high-precision \#1.5 coverslips (10,000 cells/cm^2^), for co-immunoprecipitations, cells were plated in 6-well plates (300,000 cells/cm^2^). Transfections were performed using Lipofectamine 2000 according to the manufacturer's protocol. In all experiments, the total amount of plasmid DNA was normalized with empty pcDNA or pCAGGS plasmids. Cells were cultured for 2 days after transfection and fixed with 4% PFA/ 4% sucrose in PBS.

### Antibodies {#sec4.4.5}

A rabbit polyclonal antiserum was raised against a cytosolic C-terminal PRG2 peptide (CAESYYRRMQARRYQD; Eurogentec). Antibodies were affinity-purified by Sulfolink column chromatography (Thermo Scientific). A rabbit antibody against PRG2 (AP5732c) from Abgent was also used in some experiments. The rabbit anti-PRG1 antibody was from R&D Systems (\#MAB2874). Rabbit anti-PTEN (\#9559), rabbit anti-AKT (\#9272) and rabbit anti-pSer473AKT (\#4060) were from Cell Signaling. Goat anti-PTEN (N19) was from Santa Cruz Biotechnology. Mouse anti-Flag antibody (F1804), mouse anti-MAP2 (M9942), mouse anti-α-tubulin (T6199) and anti-Flag Affinity Gel (A2220) was from Sigma. Chicken anti-GFP antibody (ab13970) was from Abcam, the mouse anti-Tau1 (MAB3420) and mouse anti-GAPDH (CB1001) from Millipore. Rabbit anti-Tubulin β-3 (Tuj1) (PRB-435P) was from Covance. HRP-conjugated anti-rabbit and anti-mouse secondary antibodies (\#PI1000, \#PI2000) were from Vector Labs and HRP-conjugated anti-chicken antibodies (G135A) from Promega. All fluorophore conjugated secondary antibodies were purchased from Jackson lab.

### DNA constructs and plasmids {#sec4.4.6}

*Prg2* cDNA (obtained from ABgene Surrey, UK; clone ID 6808849, GenBank: [BC066006](ncbi-n:BC066006){#intref0055}) was amplified by PCR using the primers P1: 5′- AAGCTTgtcaccATGCTTGCTATGAAGGAGAA-3′ and P2: 5′-tggttaactcgagGTCGACGTCCTGGTACCTC-3′, introducing a HindIII site and a Kozak sequence at the 5′ and a SalI site at the 3′ of *Prg2* cDNA, eliminating the stop codon. 3xFlag sequence was amplified by PCR from a *PTEN-3xFlag* plasmid ([@bib30]) using the primers P3: 5′-GAGGTACCAGGACGTCGACctcgagttaacca-3′ and P4: 5′-ACCGGTTTAggtacccttgtcatcgtca-3′. The P4 primer introduced an in-frame stop codon followed by an AgeI site. The amplified *Prg2-Flag* sequence was cloned into a pGEM vector and subcloned into pCAGGS (provided by I. Lieberam, King's College London) using an SphI/NotI fragment; subcloning to HindIII/XmaI-digested p2Lox plasmid for generation of ESC clones ([@bib36]) used a HindIII/AgeI fragment. The *Prg2ΔC*- sequence (1-1221 bp corresponding to the first 407 amino acids of PRG2) was amplified similarly using P1 and P2′ primers: 5′-tggttaactcgagGTCGACACCGATAAGCT-3′ and subcloned as a HindIII/SalI fragment in-frame into the pGEM- *Prg2-Flag* plasmid generating pGEM- *Prg2ΔC-Flag* and further subcloned int pCAGGS-plasmid generating pCAGGS-*Prg2ΔC-Flag*. *Prg2-YFP* plasmid was constructed using P1 and P2yfp primers (P2yfp: 5′-tggttaactcgagGTCGACTTGTCCTGGTACCTC-3′) for amplification of *Prg2* cDNA and cloning of a HindIII/SalI fragment in frame to pEYFP-N1 vector. For viral infection under CAG promoter, *Prg2-Flag* and *Prg2ΔC-Flag* fragments were PCR-amplified (P5: 5′-GCTAGCgtcaccATGCTTGCTATG-3′ and P6: 5′-AAGGCGCGCCTTACTTGTCATCGTCATCC-3′) introducing NheI and AscI restriction sites into the modified FUGW lentiviral shuttle vector comprising a CAG promoter. For live-cell imaging, *Prg2* was tagged N-terminally with *Halo* amplified from pFC14A HaloTag® CMV Flexi® Vector (Promega, \#G9651) using P7 (5′-gagCTAGCgccaccatggggtccgaaatcg-3′) and P8: (5′-CATggatccgccgccaccagacccacctccgccggagccaccgccggaaccggaaatctc-3′) primers and subcloned using NheI/BamHI into a pCAGGS plasmid. *Prg2* harboring a C-terminal Stop codon was amplified with primers P9: 5′-GAGCTGTACAAGtccggcggtggctccggcggaggtgggtctggtggcggcggatccATGCTTGCTATG-3′ and P10: 5′-gtcgcggccgctTTAGTCCTGGTACCTC-3′ and subcloned as a BamHI/NotI-fragment into pCAGGS-Halo. *GFP-UtrCH* was a gift from William Bement (Addgene plasmid \# 26737). *Prg1-GFP, Prg3-GFP, Prg4-GFP and Prg5-GFP* were kindly provided by Antje Bräuer (Carl von Ossietzky University Oldenburg).

pCAX plasmids expressing *GFP-PTEN* wild-type, the phosphatase-inactive *PTEN*^*C124S*^ (CS) mutant and pCMV-*GFP-AKT* plasmids were described previously ([@bib2], [@bib30]). *mRFP-PHAKT* ([@bib25]) was a gift from P. De Camilli (Yale School of Medicine, New Haven, CT, USA), *F-GFP* plasmid expressing a farnesylated version of GFP was provided by Kai Murk (Charité-Universitätsmedizin Berlin, Germany) and *GFP-SHIP2* was provided by Nick Leslie (Heriot-Watt University, Edinburgh, Scotland). *GFP-UtrCH* was a gift from William Bement (Addgene plasmid \# 26737, [@bib7]). The *Pten* RNAi (5′ CGACTTAGACTTGACCTATAT 3′) targeting mouse *Pten*, and scrambled RNAi (5′ CAACAAGATGAAGAGCACCAA 3′) sequences were used as previously described ([@bib50]). The constructs were generated by sub-cloning an inverted repeat, separated by 9-nucleotide loop, into the modified FUGW lentiviral shuttle vector using BamHI/PacI restriction sites under U6 promoter. As a transduction marker, the shuttle vector contained a synapsin promoter-controlled RFP cassette with nuclear localization signal (NLS).

### Expression analysis and immunoprecipitation {#sec4.4.7}

Total RNA from primary mouse cortical neurons of different days *in vitro* (DIV) was purified using the BioReagents SurePrep RNA/DNA/Protein Purification Kit (Thermo Fisher Scientific; \#BP2802) according to the manufacturer's protocol. Contaminating genomic DNA was degraded with DNase I (Roche; \#04716728001) prior to cDNA synthesis from 2 μg total RNA using random hexamer primers from the Transcriptor First Strand cDNA Synthesis Kit (Roche; \#04379012001). Intron spanning primers for *Prg2* (fw: 5′ gaataaaacgccgaaggaca 3′, rev: 5′ aagccacgatgggtagctc 3′), *Prg1* (fw: 5′ accatccagtcgatgtctattgt 3′, rev: 5′ agcatactgtcttcactaggcaaa 3′) and *Tubulin* (fw: 5′ gcgcatcagcgtatactacaa 3′, rev: 5′ catggttccaggttccaagt 3′), and corresponding recommended probes (*Prg1*: UPL \#63, *Prg2*: UPL \#51, *Tubulin*: UPL \#81) were selected using the Roche Universal ProbeLibrary assay design center. Each primer set was tested for efficiency and real-time PCRs were performed with primers with efficiency close to 100% using the LightCycler® 480 Probes Master kit (Roche; \#04707494001) on LightCycler® 480 (Roche). Abundance of *Prg2* and *Prg1* transcripts in neurons was quantified relative to Tubulin at different ages using the dC~t~-Method.

Protein lysates from cell lines, neurons and brain tissue were prepared in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate), supplemented with EDTA 2 mM and protease and phosphatase inhibitor cocktails from Calbiochem (539134) and Sigma (P5726). For co-immunoprecipitations and PTEN phosphatase assay, a PTEN lysis buffer consisting of 50 mM Tris pH 7.8, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, supplemented with 0.1% β-mercaptoethanol and protease inhibitor cocktail was additionally used. Protein samples for western blotting were prepared with 4x Roti-Load 1 (Roth), loaded on 8% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked with 5% skim milk in TBST for 30 min. Primary antibodies were prepared at a dilution of 1:1000 in 5% skim milk/TBST and incubated overnight at 4°C. After washing and incubation with secondary HRP-conjugated antibodies, the ECL signal (Promega) was detected and imaged using the Fusion SL system from Vilber Lourmat.

Flag-tagged proteins were immunoprecipitated by incubating pre-cleared protein lysates with anti-Flag M2 affinity gel for 2 h at 4°C and after three to four washes with RIPA buffer, precipitated protein complexes were eluted by boiling in 2x Roti-Load buffer. For PTEN and SHIP2 immunoprecipitation, protein lysates were first pre-cleared with protein G agarose for 1 h at 4°C and then incubated overnight with 2 μg anti-PTEN goat antibody (N19, Santa Cruz) or 0.2 μg anti-GFP rabbit antibody (Roche). Protein immunocomplexes were captured by incubation with protein-G-agarose beads for 2 h, washed and eluted as above.

### PTEN and SHIP2 phosphatase assays {#sec4.4.8}

GFP-PTEN immunoprecipitates from transfected COS-7 cells were washed four times with PTEN lysis buffer and three times with PTEN assay buffer (100 mM Tris pH 8.0, 2 mM DTT). After the final wash, beads were resuspended in assay buffer, distributed in 25 μL aliquots and placed on ice. In preliminary experiments, we established the specificity of the assay using wild-type and phosphatase-inactive PTEN with di-C8-PI(3,4,5)P~3~ (P-3908, Echelon Biosciences) as substrate. We also established that assaying 5% of total immunoprecipitated PTEN from a 6-well plate results in linear kinetics of PI(3,4,5)P~3~ hydrolysis for up to 30 min. We followed this protocol in all subsequent experiments to ensure assay linearity. One-tenth of the immunoprecipitation reactions was kept for analysis of PTEN levels by western blotting. Reactions were started by the addition of 3 μL of 1 mM di-C8-PI(3,4,5)P~3~ to a 25 μL-aliquot of immunoprecipitated PTEN and samples were incubated at 37°C under constant rotation for up to 60 min. Reactions were terminated by addition of 100 μL malachite green reagent, and after a further incubation for 15 min at room temperature, absorbance at 620 nm was measured. Released inorganic phosphate was calculated using a phosphate (KH~2~PO~4~) standard curve. For SHIP2 phosphatase assays, we used an assay buffer consisting of 50 mM Tris, pH 7.2, 5 mM MgCl~2~. The specificity of this assay was also determined using wild-type and phosphatase-inactive SHIP2 (lacking the catalytic domain) with both di-C8-PI(3,4,5)P~3~ and di-C8-PI(4,5)P~2~ as substrates (data not shown).

### Purification of PRG2 and MST binding assays {#sec4.4.9}

*Prg2* was tagged with a C-terminal Rhodopsin 1D4 epitope (Rho1D4) in a pMT4 vector and expressed in HEK293S GnTI^-^ cells using polyethylenimine (PEI; Sigma) with 3:1 (v/v) ratio of PEI:DNA for transient transfection. Cells were centrifuged at 4,000 g and the pellet was washed twice with PBS, and lysed in 20 mM HEPES pH 7.4, 150 mM NaCl, 1% (w/v) Fos-Choline-14 (Anatrace) supplemented with protease inhibitors, using gentle agitation for 1 h at 4°C. Solubilized proteins were incubated overnight with Rho1D4 Agarose (Cube Biotech) and after washing with 20 mM HEPES pH 7.4, 150 mM NaCl, 0.01% (w/v) Fos-Choline-14, Rho1D4-tagged PRG2 was eluted by addition of 200 μM Rho1D4 peptide (Cube Biotech, 16201) overnight. Following collection of the Rho1D4-tagged PRG2 eluate, the detergent was exchanged with amphipol (A8-35; Anatrace). For the substitution process, 1% (w/v) A8-35 was added and incubated for 1 h. Active Bio-Beads were then added and detergent was removed overnight. The purity of PRG2 was characterized with SDS-PAGE followed by Coomassie staining and western blotting. The tagged protein was concentrated to 20 μM using a 100 kDa cut-off Amicon Ultra-0.5 mL centrifugal filter (Merck), and fluorescently labeled using the Monolith Protein Labeling Kit RED-NHS (NanoTemper Technologies) according to the manufacturer's protocol. Excess dye was eliminated and protein purified by size-exclusion chromatography on a Superose 12 10/300 GL column (GE Healthcare), pre-equilibrated with 20 mM HEPES pH 7.4, 150 mM NaCl. The protein peak was collected for MST measurements.

MST was measured on a Monolith NT.115 device (NanoTemper Technologies) using 32.5 nM fluorescently labeled PRG2 in 20 mM HEPES pH 7.4, 150 mM NaCl, 0.05% (v/v) Tween 20. Samples were added to standard capillaries (NanoTemper Technologies), and MST was measured at 9-10°C with 20% IR laser power using medium MST power settings. Sixteen-fold serial dilutions of 2.5 μM PTEN (OriGene) in 25 mM Tris-HCl pH 7.3, 100 mM glycine, 10% (v/v) glycerol were prepared, mixed with a constant concentration of labeled PRG2. Measurements were repeated seven times in two independent PRG2 sample preparations. Data were analyzed using the MO.Affinity analysis software (NanoTemper Technologies). The dissociation constant K~D~ between PRG2 and PTEN was calculated using the software's standard fitting mode derived from the law of mass action with a fixed lower border at the lowest measured F~norm~.

### Immunochemistry and image acquisition {#sec4.4.10}

Paraformaldehyde-fixed cells (N1E-115 cells, U87MG cells, primary neurons and ESCMNs) were washed three times with PBS, permeabilized in 0.2% Triton X-100 for 5 min and then blocked in blocking buffer (5% bovine serum albumin in PBS or 4% normal goat serum in PHEM) for 1 h. Cells were then incubated with primary antibodies in blocking buffer and after washes with PBS, were incubated with appropriate Alexa dye-conjugated secondary antibodies (Jackson labs and Invitrogen). Actin filaments were labeled using Alexa-conjugated Acti-stain (Cytoskeleton) or Phalloidin-Alexa647 (Invitrogen). Proximity ligation assays (PLA) were performed using Duolink reagents (Sigma). Briefly, GFP-coupled proteins were detected using rabbit anti-GFP, Flag-coupled PRG2 was detected using mouse anti-Flag with corresponding secondary anti-rabbit PLA-Plus and anti-mouse PLA-Minus antibodies. Duolink PLA reagents were used according to the manufacturer's protocol for ligation, amplification and mounting. Images were acquired with a Leica TCS SP5 confocal microscope or a Nikon Eclipse Ti epifluorescence microscope. For 3D structured illumination microscopy (SIM), N1E cells as well as hippocampal or cortical neurons were plated on acid-washed, poly-ornithine/laminin-coated high-precision \#1.5 coverslips (Carl Roth LH24.1). N1E cells were transfected with *Prg2-Flag* as described above and fixed two days later with 0.2% GA, 4% PFA, 4% sucrose in PHEM buffer and stained for Flag, Tubulin and F-actin. Neurons were fixed at DIV7-9 with 4% PFA/15% sucrose in PBS and stained for PRG2, Tau and F-actin. Neurons were mounted with Vectashield (H1000, Vector Laboratories), N1E cells with ProLong Gold antifade reagent (Invitrogen). Image acquisition was undertaken on an OMX V4 Blaze system (GE Healthcare) using the 488 nm, 568 nm and 647 nm laser lines, standard filter sets and 125 nm z sectioning. 100 nm fluorescent beads (Tetraspeck, T7284, Thermo Fischer Scientific) were used for registration of the detection channels, achieving less than 40 nm registration error for all three channels.

For immunohistology, brains of E16.5 mice were dissected on ice and fixed overnight in 4% PFA in PBS at 4°C. Brains were then washed with PBS and incubated with 15% sucrose in PBS for 8 h at 4°C before exchanging the 15% sucrose with 30% sucrose in PBS for overnight incubation. Brains were then embedded in OCT and 20 μm coronal sections were cut on a cryostat. Sections were permeabilized with 0.2% Triton X-100 in blocking buffer at room temperature for 1 h, and stained using anti-PRG2 (dilution 1:200), anti-L1 (Merck, MAB5272, dilution 1:500). Sections were mounted in 80% glycerol with 2.5% DABCO.

All live-imaging of primary hippocampal neurons was performed at 3-4 DIV. Neurons were transfected at DIV1 as described above with 0.3 μg of *UTR-GFP* and 0.5 μg of *Halo-Prg2* per well. Prior to imaging, cells were labeled with Janelia Fluor 646 HaloTag ligand (Promega) at a final concentration of 100 nM. Briefly, one-tenth of the culture medium was replaced with the HaloTag ligand and incubated at 37°C 5% CO~2~ for 15 min. The medium was then replaced with Neurobasal A medium minus phenol red (GIBCO) (supplemented as described above). Additionally, 50 ng/ml of human recombinant BDNF (R&D systems) was added to the imaging medium to promote filopodia formation. Healthy-looking cells with medium-level expression of the constructs were selected and only the most distal part of the main axon was imaged. Imaging was performed on Nikon Spinning Disk Confocal CSU-X under controlled temperature (37°C), CO~2~ (5%) and humidity conditions, using an oil-immersed 100x 1.45 NA objective and ND Acquisition software. 488nm and 647 nm laser lines with 300 ms exposure time were used for triggered acquisition of z stacks. Each axon was imaged for 10 minutes with no delay between frames resulting in a focal plane interval of 8 s.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Morphometry analyses {#sec4.5.1}

For morphometric analyses of U87MG cells expressing *Prg2* and *PTEN* variants, maximum intensity projection images were acquired of random fields on a Leica TCS SP5 confocal microscope. U87MG cells were scored for the presence or absence of peripheral F-actin foci, most frequently appearing as peripheral lamellipodia at the cell edges, or for the presence or absence of PH-AKT plasma membrane accumulations/foci, depending on the experiment. Results from 2-4 transfections of 2-3 different cell batches were pooled. For PH-AKT plasma membrane accumulation ([Figure 3](#fig3){ref-type="fig"}C), data is from n = 60 (GFP), 52 (PTEN^C124S^), 50 (PTEN^WT^) and 64 (PTEN^WT^+PRG2) cells. For peripheral F-actin foci ([Figure 3](#fig3){ref-type="fig"}E), data is from n = 100 (GFP), 50 (PRG2), 91 (PTEN), 64 (PTEN+PRG2) and 66 (PTEN+PRG2ΔC) cells.

Analysis of PRG2 localization on axonal and dendritic processes was undertaken by acquiring high magnification images of PRG2-stained hippocampal neurons on a Leica TCS SP5 confocal microscope. Selected individual processes identified as dendritic (MAP2-positive) or axonal (MAP2-negative or Tau-positive) of similar widths were analyzed by drawing vertical lines crossing the process, running line intensity profiles and normalizing intensity values using the quantify mode of LAS AF software (as shown in [Figure S2](#mmc1){ref-type="supplementary-material"}). We calculated the ratio of maximum peak to maximum valley intensities along these vertical lines; depending on whether these occur toward the edge or the middle of the process the ratio provides a measure of membrane localization, with high values (\> 1) indicating membrane enrichment.

Analysis of super-resolution images of PRG2 and F-actin localization was undertaken using FIJI ([@bib47]). Tau-positive axons were manually traced sequentially using the measurement point function. For analysis of the frequency distribution of PRG2 spots ([Figure S7](#mmc1){ref-type="supplementary-material"}D-F) and the average spacing of consecutive PRG2 spots ([Figure 4](#fig4){ref-type="fig"}F), regions of an axonal process longer than 1.5 μm were included. For analysis of the effect of Latrunculin treatment on PRG2 localization and membrane abundance, control and treated DIV9 hippocampal neurons were stained and tracked as above. Results were pooled from a total axonal length of 174.36 μm / 553 spots (control), 171.95 μm / 377 spots (Latrunculin, 1h) and 183.00 μm / 364 spots (Latrunculin, 3h) from 9 neurons per condition. In all cases, example images were adjusted for brightness/contrast within linear ranges using Fiji/ImageJ when necessary. Control and experiment conditions were adjusted with the same parameters.

Analysis of axonal filopodia in ESCMNs was undertaken by acquiring images of GFP- or Tuj1-stained and F-actin-stained neurons. Axons were traced in the GFP or Tuj1 images and numbers and lengths of filopodia were traced in the F-actin images using the NeuronJ plug-in of FIJI ([@bib40], <https://imagescience.org/meijering/software/neuronj/>). Only filopodia longer than 2.5 μm were included in the analysis. The number, total filopodia length, length of the longest filopodium, as well as the average length per traced axon were calculated. In ESCMNs grown for 20 h and stained for Tuj1, we traced axons (defined as the longest process) and number of branches/axon. Results from 2-3 separate ESCMN differentiation/isolation experiments with neurons plated in triplicate coverslips were pooled. For axonal filopodia measurements ([Figure 5](#fig5){ref-type="fig"}D) data is from 102-167 cells. For branch measurements ([Figure 5](#fig5){ref-type="fig"}F), we included data from 155-227 cells.

Morphometric analysis of hippocampal neurons was performed on F-actin and Tau-stained stage 3 neurons grown on poly-ornithine/laminin-coated coverslips imaged on a Nikon Eclipse Ti epifluorescence microscope with a 40x lens. All processes of the neurons were traced and classified as axons (defined as the Tau-positive and longest neurite), dendrites (defined as 'other' neurites). Axonal branches and axonal filopodia were measured using the NeuronJ plug-in (FIJI), processes longer than 10 μm were considered branches. Mean and maximal lengths of axons, dendrites and filopodia as well as filopodia density on the axon shaft and number of dendrites per cell were calculated using a custom script in the statistics software R. In each genotype, 61-69 cells were quantified in four independent cultures derived from *Prg2* x Het crossings.

Morphometric analysis of branching in stage 4 hippocampal neurons was performed in *GFP*-transfected neurons (transfection at DIV3) fixed at DIV5 and stained for GFP and Tau. *Prg2-Flag* or *Prg2ΔC-Flag* were reconstituted in separate but similarly treated *Prg2 −/−* cultures at DIV1 using viral infection. Effects of *Pten*-knockdown were analyzed in separate cultures additionally infected with shRNA against *Pten* (*shPten*) or a scrambled control (*Scr*) at DIV1, *shPten* virus was used in identical (3^rd^) or double volume (4^th^ lane) compared to *Scr* virus (2^nd^ lane in [Figure 7](#fig7){ref-type="fig"} B). All neurites were traced in the GFP-images and classified as axons (defined as the Tau-positive and longest neurite), dendrites (defined as other neurites), as well as primary, secondary and tertiary axonal branches using the NeuronJ plug-in. All data were calculated using a custom script in the statistics software R. To reduce the complexity of the dataset in [Figure 6](#fig6){ref-type="fig"}G, neurons of equal axon lengths were grouped into clusters of equal size and means of branches and axon length for these clusters were used to determine the correlation of total branches and total axon length using Excel. The branching analysis of WT against *Prg2 −/−* was performed on 99-119 cells per genotype from three independent cultures of *Prg2*-Het x Het crossings. The effect of *Pten* shRNA was assessed in 131-148 cells per genotype from five independent cultures. PRG2 and PRG2-ΔC reconstitution experiments were performed with 88-97 cells per condition from four independent cultures.

### Classification of PRG2- and F-actin clusters {#sec4.5.2}

To assess local effects of PRG2 on Filopodia formation, we first quantified co-localization of newly forming filopodia with both PRG2- and F-actin clusters ("patches"). Initially, confocal z stacks were reduced by max projection, fluorophore beaching was corrected by histogram matching (<https://imagej.net/Bleach_Correction>) and drift was corrected by the "MultiStackReg" plugin (<https://github.com/miura/MultiStackRegistration>) of FIJI. Movies were cropped to 20 μm axon stretches with (if possible) emerging filopodia in the center.

Signals of both Halo-PRG2 and GFP-Utrophin were classified as clusters if their mean intensity was at least 20% brighter than the intensity of an adjacent area in the axon. Filopodia were classified to (a) emerge directly from a cluster, (b) in vicinity to a cluster (\< 1.5 μm distance to the border) or (c) without a nearby cluster.

### Nearest neighbor analysis of timelapse data {#sec4.5.3}

To test for specificity of co-localization, we performed a nearest neighbor analysis on time-lapse data. Coordinates from filopodia and PRG2 spots were determined from max-projected movies in FIJI and the nearest neighbor (NN) analysis was conducted in a custom written python script (<https://github.com/ngimber/NearestNeighborWorkflow_Filopodia>), which was run in a Jupyter Notebook.

Newly emerging filopodia were identified from both the actin and PRG2 channel. In the frame before protrusion of the filopodium, the brightest points of all PRG2 clusters were detected with the local maxima function of FIJI and refined manually to exclude noise. The coordinates of emerging filopodia were determined manually as the center of the filopodium base on the plasma membrane in the PRG2 channel.

The distance to the nearest PRG2 maximum in the axon was calculated for each newly formed filopodium. To test, whether the resulting nearest neighbor distribution reports a spatial relation between PRG2 and filopodia, or spatial randomness, all PRG2 spots from the frame of filopodium appearance were randomly placed inside a binary mask of the corresponding axon shaft, created from the merge of actin and PRG2 channels by excluding non-neuronal background with a manual intensity threshold. Nearest neighbor distances to the random spots were calculated for each filopodium (with 1000 iterations). Attraction and repulsion at a certain nearest neighbor distance were plotted as the ratio (measured data -- random) / random. Confidence intervals were calculated from all randomized nearest neighbor distributions and Bonferroni corrected. The difference between the medians of the measured and the simulated data were calculated for each single filopodium and this distribution was tested against zero using a Wilcoxon Signed Rank Test. Analyses included 73 newly formed filopodia from 4 independent experiments.

### Statistics {#sec4.5.4}

Sample sizes were not chosen based on pre-specified effect size. Instead, multiple independent experiments were carried out using several biological replicates as detailed in the figure legends and [Method Details](#sec4.4){ref-type="sec"} sections. The imaging and analysis of filopodia and branching in hippocampal axons was undertaken blinded to both genotypes and shRNA-treatment.

Statistical analysis was performed using GraphPad Prism 5 (Graph Pad Software, La Jolla, USA), and the significance level was set to p \< 0.05. Data are expressed as mean ± SD or means ± SEM; N describes the number of mice or independent cultures or transfections; n number of cells. Data were tested for normality and equality of variances. If not stated explicitly, Student's t tests were used to analyze differences between two conditions. One-way ANOVA with post hoc Bonferroni tests were used to analyze differences between multiple conditions.

Data and Code Availability {#sec4.6}
--------------------------

Critical analysis tools used in the study are specified in the key resource table as well as the corresponding method sections, tools generated for this study were uploaded to Github. Specifically, the script for nearest neighbor analysis performed in [Figure 7](#fig7){ref-type="fig"} was deposited to <https://github.com/ngimber/NearestNeighborWorkflow_Filopodia>.
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